
Figure 1

A


1L3-B09
Absorbance (mAU)
50
40
30
20
10
0
-10
0
1
2
3
4
5
6
Retention Volume (ml)

B




11L0-C06
Absorbance (mAU)
40
35
30
25
20
15
10
5
0
-5
0
2
4
6
8
10
12
14
16
Retention Volume (ml)

Figure 1 - continued

C



D





Figure 1 - continued

E



F




Figure 1 - continued

G




Figure 2





A
1L3-B09
100
50
0
-50
% Inhibition
1
2
3
4
Log conc. (nM)
glycosylated IL-17A
non-glycosylated IL-17A
B
11L0-C06
150
100
50
-50
% Inhibition
-2
-1
1
2
3
4
Log conc. (nM)
glycosylated IL-17A
non-glycosylated IL-17A
C
11L5-B06
150
100
50
-50
% Inhibition
-2
-1
1
2
3
4
Log conc. (nM)
glycosylated IL-17A
non-glycosylated IL-17A

Figure 2 – continued

D



E



F






Figure 3

A


2C1
150
100
50
-50
% Inhibition
-2
-1
1
2
3
Log conc. (nM)
glycosylated IL-17A
non-glycosylated IL-17A

B


A1
150
100
50
% Inhibition
-1
0
1
2
3
Log conc. (nM)
glycosylated IL-17A
non-glycosylatec IL-17A

C



B1
150
100
50
-50
% Inhibition
-2
-1
1
2
3
Log conc. (nM)
glycosylated IL-17A
non-glycosylated IL-17A

Figure 4




A
LC11L5-B06
Absorbance (mAU)
70
60
50
40
30
20
10
0
-10
0
2
4
6
8
10
12
14
16
Retention Time (min)
B
LC11L9-C09
Absorbance (mAU)
80
70
60
50
40
30
20
10
0
-10
0
2
4
6
8
10
12
14
16
Retention Time (min)

Figure 5
A


LC11L5-B06 - simultaneous inhibition of IL-17A and TNFα
Absorbance (Gro-alpha read-out)
1.2
1
0.8
0.6
0.4
0.2
0
60 nM
6 nM
0.6 nM
0.3 nM
150 pM
75 pM
37.5 pM
7.5 pM
1.5pM
200 pM TNFα + 400 pM IL-17A
200 pM TNFα
400 pM IL-17A
Medium

B



LC11L9-C09 - simultaneous inhibition of IL-17A and TNFα
Absorbance (Gro-alpha read-out)
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
60 nM
6 nM
0.6 nM
0.3 nM
150 pM
75 pM
37.5 pM
7.5 pM
1.5pM
200 pM TNFα + 400 pM IL-17A
200 pM TNFα
400 pM IL-17A
Medium

Figure 6

A



2000
1500
1000
500
0
KC serum concentration (pg/ml)
treatment (iv)
PBS
PBS
LC-B06
stimulation (sc)
+ hIL-17A

Figure 6 - continued
B




Figure 6 – continued

C




Figure 6 - continued
D





Figure 7

A


1000000
100000
10000
1000
100
10
1
serum concentration (ng/ml)
0
50
100
150
200
time (h)
LC11L5-B06 (IL-17A)
LC11L5-B06 (TNFα)

B



1000000
100000
10000
1000
100
10
1
serum concentration (ng/ml)
0
50
100
150
200
time (h)
LC11L9-C09 (IL-17A)
LC11L9-C09 (TNFα)

Figure 8

```
                                          10          20          30          40
FynSH3wt (SEQ ID NO: 20) GVTLFVALYDYEARTEDDLSFHKGEKFQILNSSE-GDWWE
1L3-B9   (SEQ ID NO:  3) GVTLFVALYDYANHGNRDLSFHKGEKFQILSTHEYEDWWE
11L0-C6  (SEQ ID NO:  4) GVTLFVALYDYKQKGHLDLSFHKGEKFQILSTHEYEDWWE
11L5-B06 (SEQ ID NO:  5) GVTLFVALYDYSARGQLDLSFHKGEKFQILSTHEYEDWWE
11L6-F03 (SEQ ID NO:  6) GVTLFVALYDYDKLSALDLSFHKGEKFQILSTHEYEDWWE
11L9-C09 (SEQ ID NO:  7) GVTLFVALYDYESVSWSDLSFHKGEKFQILSTHEYEDWWE
11L10-A05(SEQ ID NO:  8) GVTLFVALYDYSSRGVLDLSFHKGEKFQILSTHEYEDWWE
11L11-A09(SEQ ID NO:  9) GVTLFVALYDYSRKSNLDLSFHKGEKFQILSTHEYEDWWE
                         ***********       **************   *  ****

                                          50          60
FynSH3wt (SEQ ID NO: 20) ARSLTTGETGYIPSNYVAPVDSIQ
1L3-B9   (SEQ ID NO:  3) ARSLTTGETGYIPSNYVAPVDSIQ
11L0-C6  (SEQ ID NO:  4) ARSLTTGETGYIPSNYVAPVDSIQ
11L5-B06 (SEQ ID NO:  5) ARSLTTGETGYIPSNYVAPVDSIQ
11L6-F03 (SEQ ID NO:  6) ARSLTTGETGYIPSNYVAPVDSIQ
11L9-C09 (SEQ ID NO:  7) ARSLTTGETGYIPSNYVAPVDSIQ
11L10-A05(SEQ ID NO:  8) ARSLTTGETGYIPSNYVAPVDSIQ
11L11-A09(SEQ ID NO:  9) ARSLTTGETGYIPSNYVAPVDSIQ
                         ************************
```

Figure 9




Figure 10




Figure 11





Figure 12

A


1000
100
10
1
0.1
Concentration (µg/ml)
0
50
100
150
200
250
Time (h)
LC11L5-B06

B





1000
100
10
1
0.1
Concentration (µg/ml)
0
50
100
150
200
250
Time (h)
LC11L9-C09

Figure 13

A


LC11L5-B06
1000
100
10
1
0.1
Concentration (µg/ml)
0
50
100
150
200
250
Time (h)
Direct ELISA
Sandwich ELISA

B


LC11L9-C09
1000
100
10
1
0.1
Concentration (µg/ml)
0
50
100
150
200
250
Time (h)
Direct ELISA
Sandwich ELISA